Some companies chase regeneration like it is a buzzword. Amphix Bio treats it like a discipline, the kind that takes 20+ years of peer reviewed science, a Northwestern University spinout, and the patience to let biology do the talking. Founded in 2019 and spun out in 2021, this Chicago based company has been stacking proof quietly, not rushing the mic, not selling promises before the data shows up.
That discipline showed its hand on December 18, 2025, with the announcement of a $12.5M seed round, bringing total dilutive and non dilutive capital to $18M. Every existing investor followed on. No drama, no gap rounds, no awkward silence. Capital tends to vote with its feet, and here it leaned in. The syndicate is mission driven, but the signal is commercial confidence paired with regulatory progress that actually de risks the path forward.
Nick Sather, PhD, Co-founder and CEO, sits at the intersection of deep science and execution, fluent in both FDA language and investor reality. Alongside him is Samuel Stupp, PhD, Co-founder and Chief Scientific Officer, whose Northwestern University laboratory spent more than two decades building the scientific foundation. Over 100 peer reviewed publications, 30+ issued patents, and a 2021 breakthrough controlling collective molecular motion inside nanofibers. This is not academic science wandering into a startup. This is a platform with intent.
Supramolecular Therapeutic Peptides, or STPs, are the engine. These self assembling peptides act as drugs and scaffolds at the same time, forming nanostructures that activate regenerative signaling while physically supporting tissue repair. In preclinical acute spinal cord injury models, a single injection of AMFX 200 enabled motor neurons to regrow past the injury site and restore function. No cell therapy logistics. No recombinant protein complexity. Fully synthetic, scalable chemistry doing very biological work.
Regulators paid attention. AMFX 200 received FDA Orphan Drug Designation in July 2025 and completed a Type C meeting with constructive guidance on safety studies and trial design. AMFX 100, the drug device program for degenerative disc disease, earned FDA Breakthrough Device Designation in October 2024, marking the first regulatory evaluation of an STP based product. First mover status matters when the FDA is learning the category with you.
The market backdrop is real. Spinal cord injury tracks from $7.47B in 2024 toward nearly $12B by 2034, while peptide therapeutics exceed $87B with neurology as the fastest growing segment. Amphix Bio starts with acute injury, then expands into chronic SCI, ischemic stroke, Parkinson’s disease, ALS, and musculoskeletal repair, all from the same modular chemistry.
This $12.5M seed fuels IND enabling studies, manufacturing scale up, and first in human trials targeted for late 2026. It also reinforces an old truth. When science is disciplined and timing is earned, capital does not need convincing. Amphix Bio is building regeneration with rhythm, not noise, and the signal is getting harder to ignore.
Startups Startup Funding Venture Capital Seed Round Biotech NeuroTech Chemistry ChemTech Healthcare HealthTech Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring DCTalks
